Evolva today announced that it has received a $288,000 award from Cleveland Clinic led Global Cardiovascular Innovation Center (GCIC). The funding is to advance the development of Evolva’s EV-077 compound series for cardiovascular disease and to explore the formation of a dedicated cardiovascular clinical unit to be based in Cleveland, Ohio.

Evolva uses genetic chemistry technology platforms to replicate, on an industrial basis, the ability of nature to evolve molecules with exquisite "design". Evolva employs c. 65 people at locations in Switzerland, India, the USA and Denmark.

"We believe the collaboration with the GCIC and the Cleveland Clinic will give us great support in developing our most advanced molecule in the series (EV-077-3201-2) through the clinic, as well as to understand the indications we should select for other members of the series. To be working with such a leading cardiovascular centre is really exciting and we hope it is a relationship that will grow in the years to come." said Alexandra Santana Sorensen, Vice President Research & Development at Evolva.

The Global Cardiovascular Innovation Center (GCIC) is a $250 million research and product development consortium founded in 2007, the consortium is led by the Cleveland Clinic and is comprised of Case Western Reserve University, The Ohio State University, The University of Cincinnati, The University of Toledo and University Hospitals of Cleveland along with leading industry and economic development partners.

GCIC is focused on developing, incubating, and commercializing innovative cardiovascular technology for the benefit of patients worldwide and to facilitate economic development in the State of Ohio.